Session » Health Services Research - Poster II

Date: Monday, November 14, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1233

A Descriptive Analysis of Real-World Treatment Patterns of Innovator Infliximab (Remicade) and Biosimilar Infliximab in a Treatment NaïVe Turkish Rheumatologic Disease Population

9:00AM-11:00AM: Abstract Number: 1240

A Minority of Patients Utilize Most of Healthcare Resources in Rheumatoid Arthritis, Psoriatic Arthritis, Juvenile Idiopathic Arthritis, and Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1222

A Systematic Review of Consumer Perceived Health Service Needs Related to Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1230

Allopurinol Use and the Risk of Stroke in the Elderly

9:00AM-11:00AM: Abstract Number: 1238

Assessment of Mortality and Healthcare Costs Associated with Systemic Sclerosis with and without Lung Involvement

9:00AM-11:00AM: Abstract Number: 1246

Causes and Predictors of Early Readmission in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1227

Clinician-Led Development of a Standardised Term Set for Rheumatic and Musculoskeletal Disorders Allows Easy Creation of Large-Scale ICD-10 and Snomed CT Mapped Datasets from Routinely Collected Clinical Data

9:00AM-11:00AM: Abstract Number: 1220

Comparison of Healthcare Utilization of Patients with Rheumatoid Arthritis Who Are Anti-Cyclic Citrullinated Peptide Antibody Positive Versus Negative

9:00AM-11:00AM: Abstract Number: 1245

Comparison of Secukinumab Vs Adalimumab in a Cost per Responder Analysis Based on a Matching-Adjusted Indirect Comparison of Efficacy Data for the Treatment of Psoriatic Arthritis at 48 Weeks from the US Perspective

9:00AM-11:00AM: Abstract Number: 1234

Does SLE Care in a Lupus Clinic Result in Higher Quality Scores Than in General Rheumatology Clinics?

9:00AM-11:00AM: Abstract Number: 1221

Environmental Scan of Rheumatoid Arthritis Patient Registries Around the World: An Omeract Initiative

9:00AM-11:00AM: Abstract Number: 1244

Establishing a Case Report Form (CRF) for Systemic Autoimmune Diseases Studies

9:00AM-11:00AM: Abstract Number: 1226

Evaluation of the Association Between C-Reactive Protein and Anti-Citrullinated Protein Antibody in Rheumatoid Arthritis: Analysis of Two Clinical Practice Data Sets

9:00AM-11:00AM: Abstract Number: 1224

Healthcare and Research Priorities of Adolescents and Young Adults with Systemic Lupus Erythematosus: A Mixed-Methods Study

9:00AM-11:00AM: Abstract Number: 1235

Healthcare Utilization and Multimorbidities Among Adult Patients with Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 1231

Impact of Comorbidity on Health-Related Quality of Life and Healthcare Expenditure in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1232

Interdisciplinary Osteoporosis Clinical Working Group and Fracture Liaison Service at Loma Linda University Medical Center (LLUMC): Laying the Groundwork

9:00AM-11:00AM: Abstract Number: 1239

Optimizing Screening for Psoriatic Arthritis through a Shortened Psoriatic Arthritis Screening and Evaluation-2 (PASE-2) Tool

9:00AM-11:00AM: Abstract Number: 1228

Prescribing for Children with Rheumatologic Disease: Differences Between Pediatric and Adult Rheumatologists

9:00AM-11:00AM: Abstract Number: 1242

Rate of Hospitalization for Heart Failure Is Lower in Patients with Controlled Gout Versus Uncontrolled Gout

9:00AM-11:00AM: Abstract Number: 1236

Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs

9:00AM-11:00AM: Abstract Number: 1225

Serum Uric Acid Testing Practices over Five Years Among Incident Gout Cases

9:00AM-11:00AM: Abstract Number: 1229

Stakeholder Needs Assessment for a New Model of Care for Pediatric Rheumatology in Ontario

9:00AM-11:00AM: Abstract Number: 1223

The Cost of Confronting Osteoporosis:Cost Study of a Fracture Liaison Service

9:00AM-11:00AM: Abstract Number: 1237

The Economic Burden of Dermatomyositis and Polymyositis in the US

9:00AM-11:00AM: Abstract Number: 1241

Understanding Lupus Patients’ Ability to Work with Numbers

9:00AM-11:00AM: Abstract Number: 1243

Validity of the Short Form 6D Utility Measure in Early Axial Spondyloarthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].